
05/04/2025
š©āāļø A major debate is unfolding in the world of Alzheimerās care.
šÆ The Alzheimerās Associationās Revised Diagnostic Criteriaāpublished June 2024ānow allows a diagnosis based on biomarkers alone, even in people with no symptoms. The goal? Catch the disease earlier.
š² But a group of 45 international experts, writing in JAMA Neurology, pushed back. They argue this shift risks mislabeling healthy people and creating an āexplosionā of Alzheimerās diagnoses driven more by industry pressure than science.
ā”ļø Dr. Peter Whitehouse, Dr. Eric Widera, and others warn: biomarkers donāt tell the full story. Memory, behavior, and lived experience still matter. And until we know who truly benefits, we should call asymptomatic people at risk, not already sick.
ā
š